Member Info for rivaldo

Andrew Hore, "interactive investor's award-winning AIM writer", has just revealed his five AIM share tips for 2022.

SUR is the first one on his list.....

Https://www.youtube.com/watch?v=gWSYmq3EJEs

"Interactive investor
21.3K subscribers

After some great success in 2021, interactive investor's award-winning AIM writer Andrew Hore reveals his best small-cap stock ideas for 2022."

New 14 minute video interview with Tommy Cook - he always comes across extremely well.

Great to hear TC say his product is "the only one on the market" that can properly address the necessary accuracy:

Https://www.calnexsol.com/en/article-display-events/1642-tommy-cook-founder-and-ceo-calnex-solutions-plc

News this week on the refurb of the Palace of Westminster, which could now cost £14 billion - of course RNWH are already hugely involved at this location . And in addition RNWH's Seymour Civil in particular should also be benefiting from the annual costs of maintenance and other projects rising fast:

Https://www.thetimes.co.uk/article/westminster-repairs-could-last-20-years-and-cost-14bn-r35pm50h5

Extracts:

"Westminster repairs could last 20 years and cost £14bn

MPs and peers will have to move out of the Palace of Westminster for up to 20 years under a restoration plan that could take the cost of repairs to £14 billion, three times the original estimate.

The plan will be announced in the new year amid fears that the 19th-century building is falling down faster than it can be repaired. The last time MPs left was during the Blitz in 1941."

"The cost of managing the deterioration of the building is rising, and recent maintenance and continuing projects cost £127 million in one year alone. Weekly costs more than doubled between 2015 and 2019 to about £2.5 million."

Firefinch were up another 9% last night in Australia to new highs - they're now at AUS$0.82, up from AUS$0.17 in the last year. Which makes CAPD's holding in this one stock worth around £8.4m or so at present:

Https://www2.asx.com.au/markets/company/ffx

Good to see a £10k buy today cause a 2p uplift (in the spread anyway!) - hopefully indicative of not much stock around.

Merry Xmas to all here. The share price has done pretty well in 2020, up from 66p. I can't see why that shouldn't be repeated at the least in 2022 given the very low P/E multiple, the £5m cash pile, the likelihood of further acquisitions and a wider appreciation of the shift to longer-term contract wins.

CSSG have already said in the prelims outlook they recorded a "positive trading period since year end" and expect "a good first half performance in the Group's next financial year".

Worth keeping an eye on this fund's six-monthly newsletters - below 3% so not disclosable yet, they now hold 4.05m shares (as at 30/9/21), and have increased very nicely since 31/3/21 when they only held 1.27m shares:

Https://www.aegisfunds.com/documents

Aegis Value Fund are a small cap fund who say "We focus on inefficiently-priced, underfollowed stocks trading at low multiples of book value and cash flow".

It's worth noting the current EPS forecasts.

Cenkos go for 11.4p EPS for the current year, then 13.8p EPS to March'23.

Progressive Equity forecast 11.5p EPS this year, then 14.1p EPS to March'23 )and that's fully diluted adjusted EPS too).

It's no wonder on a current year P/E of barely 10, falling well into single digits - and a substantial cash pile - Cenkos say "Fair value lies in excess of twice the current price. Buy".

Good to see the share price continuing to bounce upwards - hopefully soon back to 260p just for starters in chart terms. And loads of upside to the analyst's 444p price target.

Christopher Mills talks positively about Sourcebio (03:00) here:

www.youtube.com/watch?v=cG7_82WZdmc&t=2135s

Further coverage here not posted before:

Https://www.proactiveinvestors.co.uk/companies/news/969017/sourcebio-will-get-boost-from-pcr-testing-upsurge-as-omicron-spreads-predicts-broker-969017.html

"SourceBio will get boost from PCR testing upsurge as Omicron spreads, predicts broker

The rolling average weekly PCR tests conducted is the 2nd highest since the pandemic began

Mon 13 Dec 2021

SourceBio International is well placed to benefit from the latest surge in PCR tests for Covid sparked by the Omicron variant, according to analysts at Liberum.

PCR testing volume in the UK has steadily grown in recent months with the rolling average weekly PCR tests conducted of 454,000 now the second-highest since the pandemic began, said the broker.

UK travel requirements mean that all arrivals must complete a Day 2 PCR test through an approved provider, a list that includes SourceBio.

In October, SourceBio’s PCR test was endorsed by Which? as the best provider of affordable Day 2 testing and ‘the most reliable choice for consumers.

The reintroduction of a mandatory Day 8 PCR test for UK arrival is also said to be under consideration by the government.

With the base business also now trading at pre-pandemic levels, Lberum believes SourceBio should meet forecasts for revenues this year of £86.5mln and underlying profits [EBITDA] of £21mln with potential to do even better in 2022 if more testing becomes the norm.

An update on trading is expected in early 2022 and Liberum sees potential for forecasts to be raised and has a buy rating and target price of 190p."

Hopefully this consolidation phase is setting things up nicely for an upwards breakout in the run up to the prelims next month.

Christopher Mills (Harwood Capital etc) is very positive about Sureserve (30:05) here:

www.linkedin.com/feed/update/urn:li:activity:6879354290515841026/

www.youtube.com/watch?v=cG7_82WZdmc&t=2135s

Arden today reiterate their Buy and 280p target price. They currently forecast 14.8p EPS for the year about to end, and 18p EPS for the year starting next month.

And that excludes anything received from the VW claim.

They conclude:

"Investment thesis and valuation - Anexo trades on 8.6x P/E and 6.5x EBITDA. As we discussed previously, the market provides very little value for the 20,000 case backlog and the investments made in legal services to drive settlements with very little value recognised for potential emissions claims. In our view, the market does not grasp the impact of COVID, accelerating scale and the pent-up settlement potential in the Group which will ultimately release shareholder value. Reiterate Buy"

Berenberg reiterate their Buy and 127p target:

Https://www.sharecast.com/equity/Capital_Limited_DI/broker-views

I know - it's just crazy imo! We know that the results will be very good. They may even beat upgraded expectations again. The prospects for the next couple of years for the core business are even better. The current year P/E is only around 7 and will of course reduce next month even further.

Then there's the substantial portion of the m/cap covered by the investment portfolio, which is essentially thrown in for free at present, despite growing hugely and is now at $50m or more against the £152m m/cap.

Then there's the likely flotation of Allied Gold Corp, which is likely to crystallise a further $10.9m of investment value at current valuation plus presumably an IPO premium.

Then there's the value of the fast-growing MSA Labs business, including the new Chrysos gold-testing technology.

Not to mention the expansion into waste mining services and the likely further - and probably highly material - contract wins which the directors have broadly hinted at, following the huge contract win at Centamin's Sukari pit.

Interesting recent article not posted here before:

Https://lbndaily.co.uk/new-jobs-at-mersey-brake-disc-maker/

"New jobs at Mersey brake disc maker
Last updated Dec 14, 2021

A Liverpool city region maker of brake discs for high performance supercars has seen headcount rise by 60% in 2021 and says more new high value jobs are on the way.

Specialist Merseyside high performance brake disc manufacturer Surface Transforms (ST) says it will create new jobs in 2021 after growing its workforce by 60% in 2021.

ST is based at Image Business Park in Knowsley and makes carbon fibre reinforced ceramic brake discs for high performance cars and is currently supplying them for the Aston Martin Valkyrie, a limited edition model that will cost buyers almost £3m.

Other customers have included Porsche, Ferrari and Nissan and in September the business, which is listed on the Alternative Investment Market (AIM) revealed it had a forward order book worth £70m.

etc"

on top of today's contract win.

Tanga Resources has changed its name to Wia Gold (ASX: WIA). It's raised $4.6m of new funding, and has announced good news from its recent drilling in the Ivory Coast. All the news is here:

Https://wiagold.com.au/investors/asx-announcements/

It seems CAPD has increased its holding to 40m shares (8.65%). At the current AUD0.063 - up 26% over the last year - this is now worth around £1.35m and has become a relatively material holding (asuming my calculation from Aussie dollars is correct).

Excellent news today following the reassuring RNS yesterday. The use of sustainable and high-performing materials should be highly attractive to the fashion industry who pay so much attention to these things now.

Just the start and could be a major earner relatively quickly if/when it takes off.

and gratified to see today's news that the VW case continues to go well - should be extremely material if successful, and I suspect the denouement is getting closer and closer:

Https://uk.advfn.com/stock-market/london/anexo-ANX/share-news/Anexo-Group-PLC-High-Court-Judgment-re-Volkswagen/86869706

A new $33m contract with AngloGold, securing additional revenues through to 2025 and showing the quality of CAPD's relationship with one of the mining giants:

Https://uk.advfn.com/stock-market/london/capital-CAPD/share-news/Capital-Limited-New-Contract-Award-Geita-Gold-Mi/86869767

This should get the share price moving.....

Ironic that the share price should be marked down 3% this morning on just £5k of early sells, whilst reports of huge flooding in Malaysia are now being highlighted on the BBC news, are forcing up palm oil prices and are another reason for supportive CPO prices for quite some time yet:

Https://www.nasdaq.com/articles/vegoils-palm-oil-rises-as-floods-likely-to-disrupt-harvest-process

Also FYI, a video on cashews supportive of the cashew processing investment case in general:

Https://www.businessinsider.com/why-cashew-nuts-so-expensive-nuts-2021-5?r=US&IR=T

Great news today - another £5m in the bank, with most of the revenues flagged for next year, and "We have now signed contracts for 95% of our 2022 forecasted revenues"

If that doesn't give certainty and encouragement to the markets nothing will :o))

Arden retain their Buy and 45p target price today. They see "upward pressure" on FY22 forecasts with further pipeline conversion.

Finncap retain their 44p target price. They say "the scope for upgrades in 2022 remains high".